Table 2 The distribution of neurological disorders among the study groups
Neurological disorders | COVID-19 era | p value | ||
|---|---|---|---|---|
*Group (1) (n = 441) | Group (2) (n = 679) | Group (3) (n = 285) |  | |
Vascular disease | 299 (67.8%) | 409 (60.2%) | 184 (64.6%) | 0.01* |
 Ischemic stroke | 257 (58.3%) | 340 (50%) | 161 (56.5%) | |
 Cerebral hemorrhage | 10 (2.3%) | 14 (2.1%) | 4 (1.4%) | |
 Cerebral sinus thrombosis | 17 (3.9%) | 33 (4.9%) | 10 (3.5%) | |
 Vasculitis | 15 (3.4%) | 22 (3.2%) | 9 (3.16%) | |
Autoimmune-related disorders | 67 (15.2%) | 232 (34.2%) | 52 (18.2%) | |
 GBS | 3 (0.68%) | 20 (2.9%) | 6 (2.1%) | |
 CIDP | 3 (0.68) | 5 (0.73%) | 1 (0.35%) | |
 Encephalitis | 2 (0.45%) | 8 (1.17%) | 1 (0.35%) | |
 Transverse myelitis | 13 (2.9%) | 127 (18.7%) | 13 (4.6%) | |
 MS | 19 (4.3%) | 21 (3.09%) | 6 (2.1%) | |
 Optic neuritis | 26 (5.9%) | 47 (6.92%) | 24 (8.4%) | |
 MG | 1 (0.22%) | 2 (0.29%) | 1 (0.35%) | |
 Inflammatory muscle diseases | 0 | 2 (0.29%) | 0 | |
Paroxysmal disorders | 74 (16.8%) | 33 (4.9%) | 43 (15.1%) | |
 IIH | 59 (13.4%) | 22 (3.2%) | 34 (11.9%) | |
 Status migrainosus | 4 (0.9%) | 6 (0.88%) | 3 (1.1%) | |
 Epilepsy | 11 (2.5%) | 5 (0.73%) | 6 (2.1%) | |
Others | 1 (0.22%) | 5 (0.73%) | 6 (2.1%) | |
 NPH | 0 | 4 (0.58%) | 5 (1.8%) | |
 Periodic hypokalemic paralysis | 0 | 1 (0.15%) | 1 (0.35%) | |
 Leukodystrophy | 1 (0.22%) | 0 | 0 | |
Presenting condition | ||||
 Acute COVID-19 | – | 185 (63.4%) | 107 (36.6%) | 0.5 |
 Post COVID-19 sequel | – | 108 (60%) | 72 (40%) | |